Introduction mutations remain to be elucidated. An unusual amount of truncated TDP-43, reminiscent of the truncated fragment containing the C-terminus reported earlier in inclusion bodies (19, 20) , can be observed in whole cell homogenates derived from lymphoblasts of ALS patients with TARDBP mutations (25, 27, 29). In fact, truncated TDP-43 has a tendency to aggregate since it is selectively enriched in the detergent-insoluble fraction relative to the detergent-soluble fraction, and it further accumulates upon inhibition of proteasome activity (25, 27). Additionally, levels of truncated TDP-43 containing the C-terminus accumulated when mutant M337V TARDBP, but less when WT TARDBP, were overexpressed in cell lines (26). Also, expression of two mutations (M3337V and G294A), but not WT human TARDBP, in the spinal cord of chick embryos led to arrested development due to increased apoptosis (26). Further in vitro work has demonstrated that expression of progranulin, through caspase activation, also leads to the appearance of truncated TDP-43 products, leading to translocation of WT TDP-43 from the nucleus to the cytosol (35). Interestingly both progranulin (PGRN) and TARDBP mRNAs are upregulated in the cytosol of mouse motor neurons following sciatic axotomies (36).
However, the WT TDP-43 transported from the nucleus to the cytoplasm in these motor neurons is not truncated, suggesting that C-terminal truncation is not necessary for cytosolic translocation and subsequent toxicity (36). Altogether these studies indicate a toxic gain of function due to TDP-43 translocation from the nucleus to the cytosol may lead to formation of inclusion bodies. However, a possible loss of function phenotype (e.g. due to loss of expression in the nucleus) remains an untested possibility.
In this study we validated the pathogenicity of three recently described ALS-associated TARDBP mutations (A315T, G348C & A382T) in order to determine their pathogenicity.
We first conducted experiments to test whether the expression of mutant TDP-43 in neuronal (Neuro2A) and non-neuronal (COS1) cell lines would lead to truncation, mislocalization or aggregation of TDP-43, or cell-specific toxicity. We also expressed mutant TARDBP specifically in motor neurons from primary dissociated spinal cord cultures to assess preferential toxicity in motor neurons by intranuclear injection of plasmid expression vector. This method has been used previously to create primary culture models of other motor neuron diseases, including FALS1 due to mutations in SOD1 (37, 38) . Mutant human SOD1 preferentially aggregated into inclusions and induced cell death in these cultured motor neurons and this model has been utilized in multiple studies of pathogenesis and therapeutic assessment (37, 38) . Further, using an in vivo zebrafish (Danio renio) embryo model we determined whether expression mutant human TARDBP or suppression of zebrafish tardbp is associated with selective motor neuron vulnerability early in development. Zebrafish are a well-established model used to study developmental biology because of their accessibility, optical transparency and rapid development (39, 40) . Over the past few years, this model organism has progressively become more common for the investigation of neurodegenerative disorders (41) . A major advantage of this vertebrate model is the high homology to human genes. The zebrafish tardbp (NM_201476) has a 74% nucleotide and 72% amino acid identity with its human TARDBP orthologue (NM_007375) and contains both RNA binding motifs as well as a very high identity to the C-terminus region of TDP-43 (42) . This genetic homology allows to effectively knock down (KD) specific mRNAs with anti-sense morpholino oligonucleotides (AMO) to test for loss of function or to overexpress mutant human TARDBP mRNAs to test for rescue or gain of function. We and others have used zebrafish to develop ALS models, including overexpression of mutant SOD1 (7) and KD of Alsin (43) using AMOs. Thus, we established zebrafish models to examine whether TARDBP mutations directly cause a motor neuronal phenotype in vivo and to assess the potential involvement of gain and/or loss of function.
Results

Characteristics of TARDBP mutations and cloning strategy
In order to evaluate the pathogenicity underlying TARDBP mutations found in ALS patients, three previously reported missense variants were selected (A315T, G348C & A382T) based on their being reported in more than one patient and by more than one group (Table S1 ) (24, 25, 28, 29, 31, 34). The A315T variant was observed by our group in both a classic FALS case and by Gitcho and colleagues in an individual affected by a familial lower motor neuron disease resembling ALS; in both cases the mutation segregated with the disease (24{Kabashi, 2008 #307). We observed the G348C mutation in four SALS cases from France(25), and recently it was also reported in German and Belgian FALS cases(31, 34). Finally, our group identified the A382T mutation in two FALS cases from France(25), as well as it was reported in 3 more FALS and 6 more SALS from Italy (29, 31).
To conduct tests for expression, mislocalization, aggregation and toxicity, FLAG and myc (six chains) were incorporated at the N-terminus and C-terminus of the WT 
Mutant TARDBP expression leads to selective toxicity in motor neurons
The WT and mutant TARDBP constructs described in Figure 1 were expressed in motor neurons of primary murine spinal cord-DRG cultures by intranuclear microinjection, with dextran-FITC being included in the injectate to follow these neurons in the living state by by guest on http://hmg.oxfordjournals.org/ Downloaded from epifluorescence microscopy (37, 38). In contrast to findings in cell lines (vide supra), the A315T, G348C and A382T TARDBP mutations were toxic to motor neurons relative to WT TARDBP (Figure 2A ) At six days post-microinjection the percentage of motor neurons lost relative to the number counted on day one, was A315T: 48%, G348C: 44%, A382T: 31% and WT TARDBP: 23% of motor neurons dead (A315T vs. WT p=0.001; G348C vs. WT p=0.01; A382T vs. WT p=0.03) (Figure 2B) . In order to determine whether the 23% toxicity resulting from overexpression of WT TARDBP was significant, an empty plasmid containing both FLAG and myc tags was injected in primary motor neurons at the same concentration (25 ng/µl). A similar (p=0.61) level of motor neuron death (18%) was measured at this concentration ( Figure 2B ), indicating a non-specific basal lethality due to injection of constructs.
The intracellular distribution of plasmid-derived TDP-43 was determined by immunolabeling cultures with antibodies against the c-terminal myc and N-terminal FLAG tags. Total TDP-43 was visualized using TDP-43-specific antibodies. As previously reported in cultured hippocampal neurons (50), TDP-43 was detected in both nuclear and cytosolic compartments of the perikaryon as well as in dendritic and axonal processes (Figure 2A) . Cytosolic TDP-43 is thought to play an important role in RNA transport, formation of RNA granules and as an activity-dependent signaling factor in dendrites (50) . Upon expression of WT TARDBP or the least toxic mutant A382T, both C-(FLAG: green) and N-termini (myc: red) tags were diffusely localized in the nucleus, cytosol and neuronal processes (Figure 2A) . On the other hand, perinuclear localization and aggregation of TDP-43 was observed in motor neurons injected with A315T and G348C mutant cDNA (Figure 2A ; see arrows), reminiscent of TDP-43 inclusions in motor neurons of ALS patients. Green (FLAG) and red (myc) fluorescence was quantified in nuclei, axonal and dendritic processes of these motor neurons as described in Materials and Methods. Though no change in fluorescence was observed in nuclear expression, (data not shown) dendritic and axonal expression of N-and C-termini were significantly reduced in motor neurons injected with A315T and G348C mutants as compared to WT, and the least toxic mutant A382T ( Figure 2C) . Finally, whereas for WT and the A382T mutant, labeling is similar with FLAG and myc antibodies, overexpression of the A315T and G348C TARDBP mutations induces a different distribution of FLAG and myc suggesting cleavage of TDP-43 could confer motor neuron toxicity. Thus, expression of mutant TDP-43 in motor neurons causes increased motor neuron death, and this cellular toxicity is associated with decreased expression in neurites, perinuclear accumulation and aggregation of mutant TDP-43.
Mutant TDP-43 overexpression causes a motor phenotype in zebrafish.
The data from experiments in culture pointed to preferential vulnerability of motor neurons to toxicity of TDP-43 mutants. This was validated in vivo using the zebrafish model. The embryos normally respond to a touch with a vigorous contraction that initiates a bout of swimming. Expression of mutated human TARDBP resulted in embryos with a curly tail, their spontaneous coiling ability at 24 hpf was severely impaired (data not shown) and at 48 hpf were unable and/or were delayed to swim away following a touch ( Figure 3A ; second row), indicating that there was a motor but not a sensory deficit. The phenotype was dose-dependent and most consistent, with minimal by guest on http://hmg.oxfordjournals.org/ Downloaded from lethality, at a concentration of 25 ng/µl and at this concentration we observed the phenotype ( Figure 3A ; third row) within 24 hpf in 57% of zebrafish embryos injected with G348C TARDBP mutant RNA, 47% of those injected with the A315T mutation, and in 39% of those injected with the A382T mutation but only in 17% of those injected with WT TARDBP mRNA (A315T vs. WT p=0.01; A382T vs. WT p=0.03; Figure 3C and Table 1 ). No significant (p=0.22) motor phenotype was observed upon injection of a mismatched morpholino (11%) when compared to WT TARDBP mRNA (17%) ( Table   1) . No changes in TDP-43 protein expression were observed upon injection of WT and mutant TARDBP RNAs as determined by Western blot analysis ( Figure S5 ). This phenotype was not observed in zebrafish embryos injected with dye only or non-injected (Table 1) . We also observed shorter and disorganized axons with excessive branching from motor neurons as measured by labeling with SV2 antibody, a marker of synaptic vesicles ( Figure 3B ) or with acetylated tubulin, a marker growing axons (not shown).
The length of the motor axons (p<0.001) was decreased and motor axon branching (p=0.02) was increased when fish injected solely with G348C and A315T TARDBP RNA were compared to fish injected with WT TARDBP RNA ( Figure 3B and 3D), whereas injection of A382T TARDBP caused a significant change in motor axon length (p=0.01), but no significant changes in axon branching when compared to fish injected with WT TARDBP RNA (p=0.36).
Knockdown of tardbp causes a loss of function motor phenotype in zebrafish
We designed an antisense morpholino oligonucleotide (AMO) to specifically bind and block translation of tardbp (NM_201476). Microinjection of this AMO caused a dose-dependent phenotype and at a relatively low concentration (0.1 mM) there was minimal lethality and a motor phenotype similar to that described above for overexpression of mutant human TARDBP was observed (delay or absence of touch-evoked escape response). Specifically, more than 60% of embryos injected with tardbp AMO had a curly tail phenotype and their coiling ability was severely impaired ( Figure 4A and Table 1 ). We observed shorter and disorganized motor neuronal axons following labeling with antibody against the synaptic vesicle marker, SV2, but no changes in the number of protein levels ( Figure 4C ) and no coiling defects were observed. No coiling defects were also observed upon injection of an AMO that would bind and block the translation of the tardbp-like gene (NM_198364) (data not shown), which has high homology to the Nterminus portion (including the RRM1 and 2), but has very little homology to the portion that encodes the C-terminus of TDP-43. These data suggest that the phenotype observed in zebrafish where tardbp was KD is specific to the motor behavior and could be due to down-regulation of the C-terminal region of TDP-43.
At 48 hpf, zebrafish injected with tardbp AMO were unable to swim away following a touch, even though they were sensitive to touch ( Figure 5A ; second row). This phenotype was not observed in zebrafish embryos injected with dye only or non-injected ( Figure 5A ; first row) and was rarely observed in embryos injected with a mismatched AMO ( Table 1) . The motor neuron specific phenotype caused by tardbp AMO was significantly reduced by co-injecting WT human TARDBP RNA ( Figure 5A ; third row) from 58% to 13% (p<0.001) ( Table 1 
Discussion
Several dominantly inherited mutations in TARDBP have been reported in more than one patient and by more than one group, corroborates their causative role in disease pathogenesis (Table S1 ) (24, 25, 28, 29, 31, 34), but it remains to be proven whether these mutants can induce a motor neuronal phenotype and to determine the mechanism of toxicity. In this study, the role of three new TARDBP mutations (A315T, G348C and A382T) was investigated using well-established in vitro (primary motor neurons and cell lines) and in vivo (zebrafish) experimental models. The data validate that these mutations confer toxic properties to the protein, TDP-43, of which motor neurons are particularly vulnerable, and that their expression causes a motor phenotype in zebrafish embryos. In 
Materials and Methods
Plasmids and vectors
Human TARDBP cDNA (untagged) was obtained from Open Biosystems. Site-directed mutagenesis to introduce mutations in the appropriate vectors was performed using a QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene, #200516) as previously described(44, 45). To evaluate the consequences of TARDBP mutations, we have generated cDNA constructs encoding N-(FLAG) and C-terminus (myc) tagged wild type (WT) and three TARDBP mutations, A315T, G348C and A382T subcloned into pCS2+ plasmid vectors. These constructs were used in all the experiments described here.
Cell lines
Neuro2A and Cos1 cell lines were maintained in Dulbecco's minimal essential medium 
Motor Neuron Cultures
Cultures were prepared from embryonic day 13 CD1 mice (Charles River Laboratories) as previously described (37, 38). In brief, spinal cords were removed from the embryos and dissociation by mincing and incubating with trypsin (Invitrogen), murine spinal cord cells were plated onto 18-mm glass coverslips in 12-well culture dishes at a density of 350 000-400 000. Coverslips were precoated with 10 µg/mL poly-D-lysine (Sigma). The culture medium was composed of MEM supplemented with 5 g/L glucose, 10 ng/mL nerve growth factor (BD Biosciences Clontech), 10 µg/mL bovine serum albumin ([BSA], Invitrogen), 26 ng/mL selenium (Sigma), 20 µg/mL triiodothyronine (Sigma), 10 µg/mL insulin (Sigma), 200 µg/mL apo-transferrin (Sigma), 32 µg/mL putrescine (Sigma), 9.1 ng/mL hydrocortisone (Sigma), 13 ng/mL progesterone (Sigma), and 2% horse serum (Invitrogen). The plating medium also contained 5% FCS and 1% PSN. 
Zebrafish (Danio renio)
Zebrafish were raised from a colony maintained according to established procedures and all procedures described here were carried out in compliance with the Canadian Council for Animal Care.
Injections in 1-4 cell stage blastulae were performed as previously described (42) .
TARDBP WT and mutant mRNAs were transcribed from NotI-linearized pCS2+ using SP6 polymerase with the mMESSAGE Machine Kit (Ambion). This was followed by a phenol-chloroform purification and ethanol precipitation, and diluted in nuclease-free water (Ambion). The mRNA was diluted in nuclease free water (Ambion) with 0.05% 
